Serotonin in Parkinson's disease

Behavioural Brain Research

Volumn 277, Issue , 2015, Pages 136-145

  Politis, Marios ^a,b   Niccolini, Flavia ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

5 HT; Parkinson's disease; PET; Serotonin; SERT

Indexed keywords

3 AMINO 4 (2 DIMETHYLAMINOMETHYLPHENYLTHIO)BENZONITRILE C 11; 6 FLUORODOPA F 18; ANPIRTOLINE; BUSPIRONE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PIMAVANSERIN; RACLOPRIDE C 11; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRACER; UNCLASSIFIED DRUG;

BASAL GANGLION; DEPRESSION; DOPAMINE RELEASE; DYSKINESIA; FATIGUE; FETAL TISSUE TRANSPLANTATION; FETAL VENTRAL MESENCEPHALIC TISSUE TRANSPLANTATION; GRAFT INDUCED DYSKINESIA; HUMAN; LEVODOPA INDUCED DYSKINESIA; LIMBIC SYSTEM; LOW DRUG DOSE; MOLECULAR IMAGING; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PSYCHOSIS; RAPHE NUCLEUS; REVIEW; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION; SLEEP DISORDER; TREMOR; VISUAL HALLUCINATION; WEIGHT REDUCTION; ANIMAL; BRAIN; METABOLISM; PATHOLOGY; QUALITY OF LIFE;

ANIMALS; BRAIN; DOPAMINE; HUMANS; PARKINSON DISEASE; QUALITY OF LIFE; SEROTONIN; TREMOR;

EID: 84912079277     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.07.037     Document Type: Review

References (149)

1. Fahn S., Elton R.L. Members of the UPDRS Development Committee: Unified Parkinson's Disease Rating Scale. Recent developments in Parkinson's disease 1987, vol. 2:153-164. Macmillan Healthcare Information.
2. Poewe W., Luginger E. Depression in Parkinson's disease: impediments to recognition and treatment options. Neurology 1999, 52(7):2-6.
3. Politis M., Wu K., Molloy S., GBain P., Chaudhuri K.R., Piccini P. Parkinson's disease symptoms: the patient's perspective. Mov Disord 2010, 25(August (11)):1646-1651.
4. Marsden C.D. Basal ganglia disease. Lancet 1982, 2(November (8308)):1141-1147.
5. Jellinger K.A. Pathology of Parkinson's disease. Mol Chem Neuropathol 1991, 3:153-197.
6. Samii A., Nutt J.G., Ransom B.R. Parkinson's disease. Lancet 2004, 363(9423):1783-1793.
7. Bernheimer H., Birkmayer W., Hornykiewicz O. Distribution of 5-hydroxytryptamine (serotonin) in the human brain and its behavior in patients with Parkinson's syndrome. Klin Wochenschr 1961, 39:1056-1059.
8. Kish S.J. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease. Adv Neurol 2003, 91:39-49.
9. Langston J.W. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006, 59:591-596.
10. Parent M., Wallman M.J., Gagnon D., Parent A. Serotonin innervation of basal ganglia in monkeys and humans. J Chem Neuroanat 2011, 41:256-265.
11. Wallman M.J., Gagnon D., Parent M. Serotonin innervation of human basal ganglia. Eur J Neurosci 2011, 33:1519-1532.
12. Bertler A. Occurrence and localization of catechol amines in the human brain. Acta Physiol Scand 1961, 51:97-107.
13. Mackay A.V., Yates C.M., Wright A., Hamilton P., Davies P. Regional distribution of monoamines and their metabolites in the human brain. J Neurochem 1978, 30:841-848.
14. Hornung J.P. The human raphe nuclei and the serotonergic system. J Chem Neuroanat 2003, 26(December (4)):331-343.
15. Chaudhuri K.R., Healy D.G., Schapira A.H. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006, 5:235-245. National Institute for Clinical Excellence.
16. Loane C., Wu K., Bain P., Brooks D.J., Piccini P., Politis M. Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology 2013, 80(May (20)):1850-1855.
17. Carta M., Carlsson T., Kirik D., Björklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
18. Politis M., Wu K., Loane C., Brooks D.J., Kiferle L., Turkheimer F.E., et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest 2014, 124(March (3)):1340-1349.
19. Loane C., Politis M. Positron emission tomography neuroimaging in Parkinson's disease. Am J Transl Res 2011, 3(August (4)):323-341.
20. Politis M., Piccini P. Positron emission tomography imaging in neurological disorders. J Neurol 2012, 259(September (9)):1769-1780.
21. Phelps M.E. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci USA 2000, 97:9226-9233.
22. Costes N., Zimmer L., Reilhac A., Lavenne F., Ryvlin P., Le Bars D. Test-retest reproducibility of 18F-MPPF PET in healthy humans: a reliability study. J Nucl Med 2007, 48(August (8)):1279-1288.
23. Ballanger B., Strafella A.P., van Eimeren T., Zurowski M., Rusjan P.M., Houle S., et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010, 67(April (4)):416-421.
24. Varnas K., Nyberg S., Halldin C., Varrone A., Takano A., Karlsson P., et al. Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. J Cereb Blood Flow Metab 2011, 31:113-123.
25. Ballanger B., Klinger H., Eche J., Lerond J., Vallet A.E., Le Bars D., et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Mov Disord 2012, 27:84-89.
26. Suehiro M., Scheffel U., Ravert H.T., Dannals R.F., Wagner H. [11C](+)McN5652 as a radiotracer for imaging serotonin uptake sites with PET. Life Sci 1993, 53:883-892.
27. Szabo Z., Kao P.F., Scheffel U., Suehiro M., Mathews W.B., Ravert H.T., et al. Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652. Synapse 1995, 20:37-43.
28. Szabo Z., Scheffel U., Mathews W.B., Ravert H.T., Szabo K., Kraut M., et al. Kinetic analysis of [11C]McN5652: a serotonin transporter radioligand. J Cereb Blood Flow Metab 1999, 19:967-981.
29. Szabo Z., McCann U.D., Wilson A.A., Scheffel U., Owonikoko T., Mathews W.B., et al. Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med 2002, 43:678-692.
30. Frankle W.G., Huang Y., Hwang D.R., Talbot P.S., Slifstein M., Van Heertum R., et al. Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. J Nucl Med 2004, 45(4):682-694.
31. Wilson A.A., Ginovart N., Schmidt M., Meyer J.H., Threlkeld P.G., Houle S. Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and invitro and ex vitro evaluation of 11C labelled 2-(phenylthio) araalkylamines. J Med Chem 2000, 43:3103-3110.
32. Wilson A.A., Houle S. Radiosynthesis of carbon-11 labelled N-methyl-2(arylthio) benzylamines: potential radiotracers for the serotonin reuptake receptor. J Labelled Compd Radiopharm 1999, 42:1277-1288.
33. Hummerich R., Reischl G., Ehrlichmann W., Machulla H.J., Heinz A., Schloss P. DASB-in vitro binding characteristics on human recombinant monoamine transporters with regard to its potential as positron emission tomography (PET) tracer. J Neurochem 2004, 90(September (5)):1218-1226.
34. Tohgi H., Abe T., Takahashi S., Takahashi J., Hamato H. Concentrations of serotonin and its related substances in the cerebrospinal fluid of parkinsonian patients and their relations to the severity of symptoms. Neurosci Lett 1993, 150:71-74.
35. Kerenyi L., Ricaurte G.A., Schretlen D.J., McCann U., Varga J., Mathews W.B., et al. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 2003, 60(9):1223-1229.
36. Kish S.J., Tong J., Hornykiewicz O., Rajput A., Chang L.J., Guttman M., et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008, 131(January (Pt 1)):120-131.
37. Guttman M., Boileau I., Warsh J., Saint-Cyr J.A., Ginovart N., McCluskey T., et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol 2007, 14(5):523-528.
38. Albin R.L., Koeppe R.A., Bohnen N.I., Wernette K., Kilbourn M.A., Frey K.A. Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab 2008, 28:441-444.
39. Politis M., Loane C. Serotonergic dysfunction in Parkinson's disease and its relevance to disability. ScientificWorldJournal 2011, 11:1726-1734.
40. Braak H., Del Tredici K., Rub U., de Vos R.A.I., Jansen Steur E.N.H., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
41. Politis M., Wu K., Loane C., Kiferle L., Molloy S., Brooks D.J., et al. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis 2010, 40(October (1)):216-221.
42. Khan N.L., Valente E.M., Bentivoglio A.R., Wood N.W., Albanese A., Brooks D.J., et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 2002, 52(December (6)):849-853.
43. Brooks D.J., Ibanez V., Sawle G.V., Quinn N., Lees A.J., Mathias C.J., et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990, 28:547-555.
44. Nurmi E., Ruottinen H.M., Kaasinen V., Bergman J., Haaparanta M., Solin O., et al. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT. Ann Neurol 2000, 47:804-808.
45. Koller W.C., Hubble J.P. Levodopa therapy in Parkinson's disease. Neurology 1990, 40:40-47.
46. Brooks D.J., Playford E.D., Ibanez V., Sawle G.V., Thompson P.D., Findley L.J., et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology 1992, 42:1554-1560.
47. Pavese N., Evans A.H., Tai Y.F., Hotton G., Brooks D.J., Lees A.J., et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006, 67:1612-1617.
48. Asenbaum S., Pirker W., Angelberger P., Bencsits G., Pruckmayer M., Brücke T. [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998, 105(10-12):1213-1228.
49. Doder M., Rabiner E.A., Turjanski N., Lees A.J., Brooks D.J. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 2003, 60:601-605.
50. Lees A.J., Shaw K.M., Stern G.M. Off period dystonia and on period choreoathetosis in levodopa-treated patients with Parkinson's disease. Lancet 1977, 2(8046):1034.
51. Ng K.Y., Chase T.N., Kopin I.J. Drug-induced release of 3H-norepinephrine and 3H-serotonin from Brain Slices. Nature 1970, 228(5270):468-469.
52. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., Matsunaga M. Role of serotonergic neurons in l-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999, 10(February (3)):631-634.
53. Maeda T., Nagata K., Yoshida Y., Kannari K. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered l-DOPA. Brain Res 2005, 1046(June (1-2)):230-233.
54. Kannari K., Yamato H., Shen H., Tomiyama M., Suda T., Matsunaga M. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered l-DOPA in the striatum with nigrostriatal denervation. J Neurochem 2001, 76(March (5)):1346-1353.
55. Nicholson S.L., Brotchie J.M. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur J Neurol 2002, (November (Suppl. 3)):1-6.
56. Eskow K.L., Gupta V., Alam S., Park J.Y., Bishop C. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav 2007, 87(August-September (3)):306-314.
57. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of l-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
58. Muñoz A., Carlsson T., Tronci E., Kirik D., Björklund A., Carta M. Serotonin neuron-dependent and independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol 2009, 219:298-307.
59. Bézard E., Muñoz A., Tronci E., Pioli E.Y., Li Q., Porras G., et al. Anti-dyskinetic effect of anpirtoline in animal models of l-DOPA-induced dyskinesia. Neurosci Res 2013, 77(December (4)):242-246.
60. Mignon L.J., Wolf W.A. 8-Hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease. Neuroreport 2005, 16:699-703.
61. Dupre K.B., Eskow K.L., Barnum C.J., Bishop C. Striatal 5-HT(1A) receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008, 55:1321-1328.
62. Rylander D., Parent M., O'Sullivan S.S., Dovero S., Lees A.J., Bezard E., et al. Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. Ann Neurol 2010, 68(November (5)):619-628.
63. Gil S.J., Park C.H., Lee J.E., Minn Y.K., Koh H.C. Positive association between striatal serotonin level and abnormal involuntary movements in chronic l-DOPA-treated hemiparkinsonian rats. Brain Res Bull 2011, 84(February (2)):151-156.
64. Dupre K.B., Eskow K.L., Steiniger A., Klioueva A., Negron G.E., Lormand L., et al. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on l-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berl) 2008, 199(July (1)):99-108.
65. Bezard E., Tronci E., Pioli E.Y., Li Q., Porras G., Björklund A., et al. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord 2013, 28(July (8)):1088-1096.
66. Lindvall O., Rehncrona S., Brundin P., Gustavii B., Astedt B., Widner H., et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 1989, 46(June (6)):615-631.
67. Wenning G.K., Odin P., Morrish P., Rehncrona S., Widner H., Brundin P., et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 1997, 42(July (1)):95-107.
68. Brundin P., Pogarell O., Hagell P., Piccini P., Widner H., Schrag A., et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 2000, 123(July (Pt 7)):1380-1390.
69. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001, 344(March (10)):710-719.
70. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003, 54(September (3)):403-414.
71. Politis M., Piccini P. Brain imaging after neural transplantation. Prog Brain Res 2010, 184:193-203.
72. Politis M., Piccini P. In vivo imaging of the integration and function of nigral grafts in clinical trials. Prog Brain Res 2012, 200:199-220.
73. Politis M., Lindvall O. Clinical application of stem cell therapy in Parkinson's disease. BMC Med 2012, 10(January):1.
74. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Wells T.H., Barrett J.N., et al. Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. Arch Neurol 1990, 47(May (5)):505-512.
75. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Kriek E., Qi J.X., et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 1992, 327(November (22)):1549-1555.
76. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990, 247(February (4942)):574-577.
77. Lindvall O., Widner H., Rehncrona S., Brundin P., Odin P., Gustavii B., et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 1992, 31(February (2)):155-165.
78. Henderson B.T., Clough C.G., Hughes R.C., Hitchcock E.R., Kenny B.G. Implantation of human fetal ventral mesencephalon to the right caudate nucleus in advanced Parkinson's disease. Arch Neurol 1991, 48(August (8)):822-827.
79. Widner H., Tetrud J., Rehncrona S., Snow B., Brundin P., Gustavii B., et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 1992, 327(November (22)):1556-1563.
80. Peschanski M., Defer G., N'Guyen J.P., Ricolfi F., Monfort J.C., Remy P., et al. Bilateral motor improvement and alteration of l-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalone. Brain 1994, 117(June (Pt 3)):487-499.
81. Levivier M., Dethy S., Rodesch F., Peschanski M., Vandesteene A., David P., et al. Intracerebral transplantation of fetal ventral mesencephalon for patients with advanced Parkinson's disease. Methodology and 6-month to 1-year follow-up in 3 patients. Stereotact Funct Neurosurg 1997, 69(1-4 (Pt 2)):99-111.
82. Hagell P., Piccini P., Björklund A., Brundin P., Rehncrona S., Widner H., et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 2002, 5(July (7)):627-628.
83. Ma Y., Feigin A., Dhawan V., Fukuda M., Shi Q., Greene P., et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 2002, 52(November (5)):628-634.
84. Olanow C.W., Gracies J.M., Goetz C.G., Stoessl A.J., Freeman T., Kordower J.H., et al. Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. Mov Disord 2009, 24(February (3)):336-343.
85. Politis M. Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?. BMC Med 2010, 8(December):80.
86. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Rehncrona S., et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med 2010, 2(June (38)):38ra46.
87. Politis M., Oertel W.H., Wu K., Quinn N.P., Pogarell O., Brooks D.J., et al. Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio. Mov Disord 2011, 26(September (11)):1997-2003.
88. Kefalopoulou Z., Politis M., Piccini P., Mencacci N., Bhatia K., Jahanshahi M., et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol 2014, 71(January (1)):83-87.
89. Loane C., Politis M. Buspirone: what is it all about?. Brain Res 2012, 1461(June):111-118.
90. Politis M. Optimizing functional imaging protocols for assessing the outcome of fetal cell transplantation in Parkinson's disease. BMC Med 2011, 9(May):50.
91. Shin E., Garcia J., Winkler C., Björklund A., Carta M. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease. Neurobiol Dis 2012, 47(September (3)):393-406.
92. Lane E.L., Brundin P., Cenci M.A. Amphetamine-induced abnormal movements occur independently of both transplant- and host-derived serotonin innervation following neural grafting in a rat model of Parkinson's disease. Neurobiol Dis 2009, 35(July (1)):42-51.
93. Martinez-Martin P., Rodriguez-Blazquez C., Kurtis M.M., Chaudhuri K.R. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011, 26(February (3)):399-406. NMSS Validation Group.
94. Politis M., Piccini P., Pavese N., Koh S.B., Brooks D.J. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. Exp Neurol 2008, 214(November (1)):112-116.
95. Starkstein S.E., Preziosi T.J., Bolduc P.L., Robinson R.G. Depression in Parkinson's disease. J Nerv Ment Dis 1990, 178(January (1)):27-31.
96. Dooneief G., Mirabello E., Bell K., Marder K., Stern Y., Mayeux R. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 1992, 49(March (3)):305-307.
97. Cummings J.L., Masterman D.L. Depression in patients with Parkinson's disease. Int J Geriatr Psychiatry 1999, 14(September (9)):711-718.
98. Young S.N., Smith S.E., Pihl R.O., Ervin F.R. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology (Berl) 1985, 87(2):173-177.
99. Bell C.J., Hood S.D., Nutt D.J. Acute tryptophan depletion. Part II: Clinical effects and implications. Aust N Z J Psychiatry 2005, 39(July (7)):565-574.
100. Cannon D.M., Ichise M., Rollis D., Klaver J.M., Gandhi S.K., Charney D.S., et al. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry 2007, 62(October (8)):870-877.
101. Cannon D.M., Ichise M., Fromm S.J., Nugent A.C., Rollis D., Gandhi S.K., et al. Serotonin transporter binding in bipolar disorder assessed using [11C]DASB and positron emission tomography. Biol Psychiatry 2006, 60(August (3)):207-217.
102. Hammoud D.A., Endres C.J., Hammond E., Uzuner O., Brown A., Nath A., et al. Imaging serotonergic transmission with [11C]DASB-PET in depressed and non-depressed patients infected with HIV. Neuroimage 2010, 49(February (3)):2588-2595.
103. Hashiguti H., Nakahara D., Maruyama W., Naoi M., Ikeda T. Simultaneous determination of in vivo hydroxylation of tyrosine and tryptophan in rat striatum by microdialysis-HPLC: relationship between dopamine and serotonin biosynthesis. J Neural Transm Gen Sect 1993, 93(3):213-223.
104. Kuhn D.M., Arthur R.E. l-DOPA-quinone inactivates tryptophan hydroxylase and converts the enzyme to a redox-cycling quinoprotein. Brain Res Mol Brain Res 1999, 73(November (1-2)):78-84.
105. Borah A., Mohanakumar K.P. Long-term l-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats. Cell Mol Neurobiol 2007, 27(December (8)):985-996.
106. Navailles S., Bioulac B., Gross C., De Deurwaerdère P. Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease. Neurobiol Dis 2010, 38(April (1)):136-143.
107. Navailles S., Benazzouz A., Bioulac B., Gross C., De Deurwaerdère P. High-frequency stimulation of the subthalamic nucleus and l-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease. J Neurosci 2010, 30(February (6)):2356-2364.
108. Eskow Jaunarajs K.L., Dupre K.B., Ostock C.Y., Button T., Deak T., Bishop C. Behavioral and neurochemical effects of chronic l-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat. Behav Pharmacol 2010, 21(October (7)):627-637.
109. Sharp S.I., Ballard C.G., Ziabreva I., Piggott M.A., Perry R.H., Perry E.K., et al. Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord 2008, 26:330-338.
110. Mayeux R., Yaakov S., Cote L., Williams J.B.W. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984, 34:642-646.
111. Kostic V.S., Djuricic B.M., Covickovic-Sternic N., Bumbasiveric L., Nikolic M., Mrsulja B.B. Depression and Parkinson's disease:possible role of serotonergic mechanisms. J Neurol 1987, 234:94-96.
112. Boileau I., Warsh J.J., Guttman M., Saint-Cyr J.A., McCluskey T., Rusjan P., et al. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov Disord 2008, 23(12):1776-1780.
113. Politis M., Wu K., Loane C., Turkheimer F.E., Molloy S., Brooks D.J., et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010, 75:1920-1927.
114. Mayeux R., Stern Y., Williams J.B., Cote L., Frantz A., Dyrenfurth I. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry 1986, 143:756-759.
115. Beyer P.L., Palarino M.Y., Michalek D., Busenbark K., Koller W.C. Weight change and body composition in patients with Parkinson's disease. J Am Diet Assoc 1995, 95(9):979-983.
116. Abbott R.A., Cox M., Markus H., Tomkins A. Diet, body size and micronutrient status in Parkinson's disease. Eur J Clin Nutr 1992, 46:879-884.
117. Uc E.Y., Struck L.K., Rodnitzky R.L., Zimmerman B., Dobson J., Evans W.J. Predictors of weight loss in Parkinson's disease. Mov Disord 2006, 21:930-936.
118. Durrieu G., Liau M.E., Rascol O., Senard J.M., Rascol A., Monstastruc J.L. Parkinson's disease and weight loss: a study with anthropometric and nutritional assessment. Clin Auton Res 1992, 2:153-157.
119. Volpi R., Caffarra P., Scaglioni A., Boni S., Saginario A., Chiodera P., et al. Defective 5-HT 1-receptor-mediated neurotransmission in the control of growth hormone secretion in Parkinson's disease. Neuropsychobiology 1997, 35(2):79-83.
120. Sjödin A., Gasteyger C., Nielsen A.L., Raben A., Mikkelsen J.D., Jensen J.K., et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond) 2010, 34(November (11)):1634-1643.
121. Politis M., Loane C., Wu K., Brooks D.J., Piccini P. Serotonergic mediated body mass index changes in Parkinson's disease. Neurobiol Dis 2011, 43(September (3)):609-615.
122. Chaudhuri A., Behan P.O. Fatigue and basal ganglia. J Neurol Sci 2000, 179:34-42.
123. Hagell P., Brundin L. Towards an understanding of fatigue in Parkinson disease. J Neurol Neurosurg Psychiatry 2009, 80(5):489-492.
124. Pavese N., Metta V., Bose S.K., Chaudhuri K.R., Brooks D.J. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010, 133(November (11)):3434-3443.
125. Goetz C.G., Wuu J., Curgian L.M., Leurgans S. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology 2005, 64(1):81-86.
126. Jahan I., Hauser R.A., Sullivan K.L., Miller A., Zesiewicz T.A. Sleep disorders in Parkinson's disease. Neuropsychiatr Dis Treat 2009, 5:535-540.
127. Jouvet M. The role of monoamines and acetylcholine containing neurons in the regulation of the sleep-waking cycle. Ergebn Physiol 1972, 64:166-307.
128. Vogel G., Cohen J., Mullis D., Kensler T., Kaplita S. Nefazodone and REM sleep: how do antidepressant drugs decrease REM sleep?. Sleep 1998, 21:70-77.
129. Hipólide D.C., Moreira K.M., Barlow K.B., Wilson A.A., Nobrega J.N., Tufik S. Distinct effects of sleep deprivation on binding to norepinephrine and serotonin transporters in rat brain. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29(2):297-303.
130. Elmenhorst D., Kroll T., Matusch A., Bauer A. Sleep deprivation increases cerebral serotonin 2A receptor binding in humans. Sleep 2012, 35(December (12)):1615-1623.
131. Lelieveld I.M., Müller M.L., Bohnen N.I., Koeppe R.A., Chervin R.D., Frey K.A., et al. The role of serotonin in sleep disordered breathing associated with Parkinson disease: a correlative [11C]DASB PET imaging study. PLoS ONE 2012, 7(7):e40166.
132. Williams D.R., Lees A.J. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005, 4(October (10)):605-610.
133. Aarsland D., Larsen J.P., Cummins J.L., Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community based study. Arch Neurol 1999, 56:595-601.
134. Marsh L., Williams J.R., Rocco M., Grill S., Munro C., Dawson T.M. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004, 63:293-300.
135. Henderson M.J., Mellers J.D.C. Psychosis in Parkinson's disease: 'between a rock and a hard place'. Int Rev Psychiatry 2000, 12:319-334.
136. Fiedman J.H. Parkinson's disease psychosis 2010: a review article. Parkinsonism Relat Disord 2010, 16:553-560.
137. Fenelon G. Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 2008, 13(3 Suppl. 4):18-25.
138. Zahodne L.B., Fernandez H.H. Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs Aging 2008, 25:665-682.
139. McFarland K., Price D.L., Bonhaus D.W. Pimavanserin a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease. Behav Pharmacol 2011, 22(October (7)):681-692.
140. Greist J.H., Jefferson J.W., Kobak K.A., Katzelnick D.J., Serlin R.C. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry 1995, 52:53-60.
141. Greist J.H., Jefferson J.W. Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry Suppl 1998, 6:4-70.
142. March J.S., Frances A., Kahn D.A., Carpenter D. The expert consensus guideline series: treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997, 58(Suppl. 4):3-72.
143. Tomer R., Levin B., Weiner W. Obsessive-compulsive symptoms and motor asymmetries in Parkinson's disease. Neuropsychiatry Neuropsychol Behav Neurol 1993, 6:26-30.
144. Alegret M., Junqué C., Valldeoriola F., Vendrell P., Martí M.J., Tolosa E. Obsessive-compulsive symptoms in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001, 70(3):394-396.
145. Matsumoto R., Ichise M., Ito H., Ando T., Takahashi H., Ikoma Y., et al. Reduced serotonin transporter binding in the insular cortex in patients with obsessive-compulsive disorder: a [11C]DASB PET study. Neuroimage 2010, 49(1):121-126.
146. Hesse S., Stengler K., Regenthal R., Patt M., Becker G.A., Franke A., et al. The serotonin transporter availability in untreated early-onset and late-onset patients with obsessive-compulsive disorder. Int J Neuropsychopharmacol 2011, 14(June (5)):606-617.
147. Perani D., Garibotto V., Gorini A., Moresco R.M., Henin M., Panzacchi A., et al. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. Neuroimage 2008, 42(August (1)):306-314.
148. Lee J.Y., Jeon B.S., Kim H.J., Park S.S. Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease. Parkinsonism Relat Disord 2012, 18(January (1)):76-78.
149. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Oertel W.H., et al. Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci Transl Med 2012, 4(April (128)):128-141.